Scientific work

Doç. Dr. Ferit Aslan

94 publications. The source of the information is stated next to each publication.

Back to profile

  1. Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

    Discover Oncology, 2026

    DOI 10.1007/s12672-026-04842-3 PMID 41870760 Open-access full textSource: OpenAlex

  2. Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG)

    Cancers, 2026

    DOI 10.3390/cancers18030394 PMID 41681877 1 citation (Europe PMC) Open-access full textSource: ORCID

  3. Electrochemical detection and DNA binding mechanism of alectinib using a green-synthesized CPE/Rc-AuNP sensor supported by spectroscopic and theoretical analyses

    Surfaces and Interfaces, 2026

    DOI 10.1016/j.surfin.2026.110701 Source: ORCID

  4. Association of Cabazitaxel Treatment Beyond 10 Cycles with Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Retrospective 8-Month Landmark Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15186966 PMID 42795739 Open-access full textSource: ORCID

  5. Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective Study

    Medicina, 2026

    DOI 10.3390/medicina62091702 PMID 42796309 Open-access full textSource: ORCID

  6. Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group

    JCO Global Oncology, 2026

    DOI 10.1200/go-26-00317 PMID 42715501 Open-access full textSource: ORCID

  7. Sustainable carbon electrode-based voltammetric method for sensitive determination of Alectinib, a targeted anti-cancer drug

    Diamond and Related Materials, 2026

    DOI 10.1016/j.diamond.2026.113830 Source: ORCID

  8. Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study

    Medicina, 2026

    DOI 10.3390/medicina62040763 PMID 42075632 Open-access full textSource: ORCID

  9. Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG)

    Cancers, 2026

    DOI 10.3390/cancers18060915 PMID 41899520 1 citation (Europe PMC) Open-access full textSource: ORCID

  10. Synchronous Adrenocortical Carcinoma, Renal Cell Carcinoma, and Mediastinal Mature Teratoma with Heterozygous Variants in SMARCA4, APC, and MYBP3: A Case Report

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-10-7 Open-access full textSource: ORCID

  11. Level II (IIA/IIB) Lymph Node Evaluation in Head and Neck Cancer: A Retrospective Cohort Study from a Non-Endemic Region

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15031068 PMID 41682748 Open-access full textSource: ORCID

  12. Early‐Onset Posterior Reversible Encephalopathy Syndrome at Reduced‐Dose Sunitinib in Metastatic Papillary Renal Cell Carcinoma: A Case Report

    Case Reports in Medicine, 2026

    DOI 10.1155/carm/7058556 PMID 42088411 1 citation (Europe PMC) Open-access full textSource: ORCID

  13. Long-Term Outcomes of Patients Undergoing Conversion Surgery After Induction Chemotherapy: Turkish Oncology Group Study

    Medicina, 2025

    DOI 10.3390/medicina61050776 PMID 40428735 Open-access full textSource: OpenAlex

  14. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70213 PMID 41147655 3 citations (Europe PMC) Source: OpenAlex

  15. Real-life efficacy and safety data of lorlatinib treatment in ROS-1–positive advanced non-small cell lung cancer: Turkish Oncology Group (TOG) study.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e20659 Source: OpenAlex

  16. Real-World Experience with Non-Metastatic Male Breast Cancer: A 222-Patient Multicenter Study from the Turkish Oncology Group (TOG)

    Cancers, 2025

    DOI 10.3390/cancers17243895 PMID 41463146 Open-access full textSource: OpenAlex

  17. Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study

    Cancers, 2025

    DOI 10.3390/cancers18010101 PMID 41514612 1 citation (Europe PMC) Open-access full textSource: ORCID

  18. Renal Cell Carcinoma in Pregnancy With Breast Metastasis: A Case Report and Literature Review

    Cureus, 2025

    DOI 10.7759/cureus.92550 PMID 41111781 Open-access full textSource: ORCID

  19. FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)

    Cancers, 2025

    DOI 10.3390/cancers17172730 PMID 40940827 Open-access full textSource: ORCID

  20. Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel

    Medicina, 2025

    DOI 10.3390/medicina61061105 PMID 40572794 4 citations (Europe PMC) Open-access full textSource: ORCID

  21. FOLFIRINOX: The best adjuvant treatment for ampullary adenocarcinoma?

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e16261 Source: ORCID

  22. Real-world treatment patterns and prognostic indicators in upper tract urothelial carcinoma: A Turkish Oncology Group (TOG) study

    European Urology Open Science, 2025

    DOI 10.1016/s2666-1683(25)01751-3 Open-access full textSource: OpenAlex

  23. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

    International Journal of Clinical Oncology, 2024

    DOI 10.1007/s10147-023-02460-5 PMID 38310597 6 citations (Europe PMC) Source: OpenAlex

  24. 71P The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: A Turkish Oncology Group (TOG) study

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.102300 Open-access full textSource: OpenAlex

  25. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2330835 PMID 38497444 7 citations (Europe PMC) Open-access full textSource: OpenAlex

  26. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.e18004 Source: ORCID

  27. Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-81371-5 PMID 39616250 2 citations (Europe PMC) Open-access full textSource: ORCID

  28. Comparison of anthracycline-containing and anthracycline-free regimens in neoadjuvant HER-2 positive breast cancer treatment

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-61562-w PMID 38724585 1 citation (Europe PMC) Open-access full textSource: ORCID

  29. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

    BMC Cancer, 2023

    DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 citations (Europe PMC) Open-access full textSource: OpenAlex

  30. 443P Efficacy and safety of CDK 4/6 inhibitors in patients with bone marrow-involved metastatic breast cancer

    Annals of Oncology, 2023

    DOI 10.1016/j.annonc.2023.09.619 Open-access full textSource: OpenAlex

  31. Application of Disposable Biosensor for Nivolumab–DNA Interaction Using Pencil Graphite Electrode

    Russian Journal of Electrochemistry, 2023

    DOI 10.1134/s1023193523110046 13 citations (OpenAlex) Source: ORCID

  32. SELEKTIF ÖSTROJEN RESEPTÖR MODÜLATÖRLERI (SERM)

    ANTINEOPLASTIK İLAÇLAR, 2023

    Source: ORCID

  33. Erişkin RabdomiyosarkomlarındaTedavi YaklaşımıTreatment Approach in Adult Rhabdomyosarcoma

    Türkiye Klinikleri, 2023

    Source: ORCID

  34. Comparison of the Efficacy and Safety of Docetaxel-Trastuzumab-Pertuzumab (DTP) with Standard 4-Doxorubicin and Cyclophosphamide (AC)-TaxanTrastuzumab-Pertuzumab in Neoadjuvant Treatment of Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER-2) Positive Breast Cancer: a Turk Oncology Group (TOG) study.

    Research Square, 2023

    DOI 10.21203/rs.3.rs-3611567/v1 Open-access full textSource: ORCID

  35. Anti-Neoplastik İlaçlar

    Akademisyen Kitabevi eBooks, 2023

    DOI 10.37609/akya.2429 Open-access full textSource: ORCID

  36. AROMATAZ INHIBITÖRLERI

    ANTINEOPLASTIK İLAÇLAR, 2023

    Source: ORCID

  37. Onkolojide İmmünoterapi

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1749 Source: OpenAlex

  38. Onkoloji

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1538 Open-access full textSource: OpenAlex

  39. Gastrointestinal Sistem Tümörleri-1

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1211 Open-access full textSource: OpenAlex

  40. Onkolojide Moleküler Hedefli Tedaviler

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1478 Open-access full textSource: OpenAlex

  41. Can fecal zonulin be used as a biomarker in the detection of leaky bowel syndrome in patients with intestinal metaplasia? A prospective cross-sectional study

    Turkish Journal of Clinics and Laboratory, 2022

    DOI 10.18663/tjcl.1160928 Open-access full textSource: ORCID

  42. Paraneoplastik Otoantikorlar

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1826.c17385 Source: ORCID

  43. Paraneoplastik Sendromlar

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1826 Open-access full textSource: ORCID

  44. Gallbladder Polyp and Cancer Evaluation After Cholecystectomy: A Retrospective Observational Study.

    Cureus, 2022

    DOI 10.7759/cureus.28089 PMID 36127982 2 citations (Europe PMC) Open-access full textSource: ORCID

  45. Glioblastoma Multiforme With CDKN2A, Loss of PTEN and EGFR Amplification, and Diffuse Distant Organ Metastasis Treated With Six Lines of Therapy: A Case Report and Literature Review.

    Cureus, 2022

    DOI 10.7759/cureus.23796 PMID 35518520 1 citation (Europe PMC) Open-access full textSource: ORCID

  46. Detection of the Metabolic Relationship Between Primary Tumor in Breast Cancer According to Molecular Classification in Positron Emission Tomography; Retrospective Cohort Study

    Medical Laboratory Technology Journal, 2022

    DOI 10.31964/mltj.v0i0.426 Open-access full textSource: ORCID

  47. Evaluation of a Year During the COVID-19 Pandemic in a Private Healthcare Facility: Retrospective Cross-Sectional Study.

    Cureus, 2022

    DOI 10.7759/cureus.23236 PMID 35449690 1 citation (Europe PMC) Open-access full textSource: ORCID

  48. Gastrointestinal Sistem Tümörleri-2

    Akademisyen Kitabevi eBooks, 2022

    DOI 10.37609/akya.1212 Open-access full textSource: OpenAlex

  49. Paraneoplastik Otoantikorlar

    2022

    Source: ORCID

  50. COVID-19 ve Kanser

    Akademisyen Kitabevi eBooks, 2021

    DOI 10.37609/akya.668 Source: ORCID